How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amlodipine-benazepril.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Amlodipine+Benazepril — Competitive Intelligence Brief

Amlodipine+Benazepril (Amlodipine+Benazepril) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker + ACE inhibitor combination. Area: Cardiovascular.

marketed Calcium channel blocker + ACE inhibitor combination L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine+Benazepril (Amlodipine+Benazepril) — TSH Biopharm Corporation Limited. Amlodipine relaxes blood vessels by blocking calcium channels, while benazepril lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE), together reducing hypertension through complementary pathways.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amlodipine+Benazepril TARGET	Amlodipine+Benazepril	TSH Biopharm Corporation Limited	marketed	Calcium channel blocker + ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Amlodipine + Perindopril	Amlodipine + Perindopril	Centre for Chronic Disease Control, India	marketed	Calcium channel blocker + ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker + ACE inhibitor combination class)

Centre for Chronic Disease Control, India · 1 drug in this class
TSH Biopharm Corporation Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine+Benazepril — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-benazepril. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab